Shares in Glaukos (NYSE:GKOS) have fallen today after the ophthalmic medical tech company posted first quarter earnings that saw profits swing to losses, despite topping The Street’s expectations. The San Clemente, Calif.-based company posted losses of $2.7 million, or 8¢ per share, on sales of $40.1 million for the three months ended March 31, seeing an […]
Glaukos
Ivantis touts 1-year head-to-head Hydrus, Glaukos iStent study data
Ivantis today released one-year results from the study of its Hydrus Microstent comparing it to Glaukos‘ (NYSE:GKOS) iStent trabecular micro-bypass stents, touting the Hydrus’ ability to reduce reliance on medication and intraocular pressure. Results from the trial were presented at the American Society of Cataract and Refractive Surgery annual meeting in Washington D.C. by Dr. David […]
Glaukos touts 2-year iStent inject pivotal trial data, levies infringement suit against Ivantis
Glaukos (NYSE:GKOS) today released two-year data from the FDA investigational device exemption pivotal trial of its iStent inject trabecular micro-bypass system, and announced a patent infringement suit it filed against Ivantis. Results of the 505-patient study were presented at the American Society of Cataracts and Refractive Surgery annual meeting by Dr. Thomas Samuelson of the Minnesota Eye […]
Ophthalmic device companies top The Street with Q4, FY2017 earnings
Ophthalmic device developers Glaukos (NYSE:GKOS) and Staar Surgical (NSDQ:STAA) this week posted fourth quarter and full fiscal year 2017 earnings that beat the streets, though only Glaukos has seen its shares rise in response. San Clemente, Calif.-based Glaukos posted profits of $1 million, or 3¢ per share, on sales of $41.7 million for the three months ended December […]
Glaukos touts IOP, medication use reductions in iStent trial
Glaukos (NYSE:GKOS) today released results from a study of its iStent trabecular micro-bypass stent exploring its use during cataract surgery in patients with severe open-angle glaucoma, touting significant reductions in intraocular pressure and medication use. The San Clemente, Calif.-based company’s iStent micro-bypass stents are made from non-ferromagnetic titanium and coated in heparin, is designed to be implanted […]
Glaukos touts Ph2 glaucoma trial for drug-eluting implant
Glaukos (NYSE:GKOS) touted data today from a Phase II trial of its travoprost intraocular implant in a 12-month cohort of glaucoma patients. The company’s iDose device is placed during a micro-invasive procedure and filled with a special formulation of travoprost – a drug used to reduce intraocular pressure. The implant continuously delivers therapeutic levels of travoprost […]
Glaukos seeks FDA IDE nod for iStent infinite trial
Glaukos (NYSE:GKOS) said today it submitted an investigational device exemption application to the FDA as it looks to launch a study of its iStent infinite trabecular micro-bypass system. The San Clemente, Calif.-based company’s iStent infinite is designed to reduce elevated intraocular pressure in patients with refractory glaucoma, and includes three heparin-coated titanium stents and an auto-injection […]
Glaukos files PMA bid for iStent Inject glaucoma treatment
Glaukos (NYSE:GKOS) said today that it filed for pre-market approval from the FDA of its iStent Inject trabecular micro-bypass stent for treating glaucoma. San Clemente, Calif.-based Glaukos said the device is designed to treat mild-to-moderate open-angle glaucoma in patients undergoing cataract surgery. It used a pair of heparin-coated titanium stents in a pre-loaded auto-injection system that allows […]
Glaukos wins FDA nod for IDE trial of iStent SA
Glaukos (NYSE:GKOS) said today it won FDA investigational device exemption to launch a pivotal study of its iStent SA trabecular micro-bypass system designed to treat glaucoma. The San Clemente, Calif.-based company’s iStent SA is designed to reduce intraocular pressure in psuedophakic, mild-to-moderate open-angle, pigmentary or psuedoexfoliative glaucoma patients, the company said. The system includes 2 micro-scale […]
Glaukos shares fall despite Q3 beat
Shares in Glaukos (NYSE:GKOS) fell today even though the ophthalmic medical device maker topped expectations on Wall Street with its third quarter results. The San Clemente, Calif.-based company posted profits of $1.3 million on sales of $40.4 million for the 3 months ended Sept.30, for bottom-line growth of 8.3% on sales growth of 36.5% compared with […]
Glaukos shares fall on Q2 sales, EPS miss
Shares in Glaukos (NYSE:GKOS) have fallen today after the diabetes-focused medical device maker missed expectation on Wall Street with its 2nd quarter earnings results. The San Clemente, Calif.-based company posted losses of $3.3 million, or 10¢ per share, on sales of $41.3 million for the 3 months ended June 30, seeing profits swing 241.6% into losses […]